Correction to: “Validation and Limitations of the PANOMEN-3 Predictive Model for Tumor Recurrence and Progression in Pituitary Tumors” - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction to: “Validation and Limitations of the PANOMEN-3 Predictive Model for Tumor Recurrence and Progression in Pituitary Tumors”

  • January 22, 2026

Share

  • 1

    The erratum addresses an error in the author list of the article on the PANOMEN-3 predictive model.

  • 2

    Julia García Arabehety's name was incorrectly published as 'Julia García' in the original article.

  • 3

    The corrected name 'Julia García-Arabehety' has been updated in the online version of the article.

  • 4

    The original article was published in the Journal of Clinical Endocrinology and Metabolism.

  • 5

    The DOI for the corrected article remains the same: 10.1210/clinem/dgaf252.

Original Source(s)

Correction to: “Validation and Limitations of the PANOMEN-3 Predictive Model for Tumor Recurrence and Progression in Pituitary Tumors”

  • January 22, 2026

Related Content

GLP-1 RAs Associated With Small ION Risk Increase

In an observational US target trial emulation, glucagon-like peptide-1 receptor agonist initiation was associated with about 3 to 4 more ischemic optic neuropathy cases per 10,000 patients over 18 months than two comparator drug classes.

CGM Linked to More Time in Range

In a randomized crossover trial of insulin-treated patients receiving hemodialysis, real-time continuous glucose monitoring did not improve the primary hypoglycemia outcome but increased time in range and reduced time above range vs capillary testing.

FDA Approves First Oral PCSK9 Inhibitor

Merck reported placebo-adjusted LDL-C reductions of 56% and 59% at week 24 in two phase 3 CORALreef trials supporting the approval.